MX367209B - Una composición intravenosa que comprende ibuprofeno y paracetamol en combinación. - Google Patents

Una composición intravenosa que comprende ibuprofeno y paracetamol en combinación.

Info

Publication number
MX367209B
MX367209B MX2015008709A MX2015008709A MX367209B MX 367209 B MX367209 B MX 367209B MX 2015008709 A MX2015008709 A MX 2015008709A MX 2015008709 A MX2015008709 A MX 2015008709A MX 367209 B MX367209 B MX 367209B
Authority
MX
Mexico
Prior art keywords
paracetamol
combination
composition including
intravenous composition
including ibuprofen
Prior art date
Application number
MX2015008709A
Other languages
English (en)
Spanish (es)
Inventor
Campbell Atkinson Hartley
Original Assignee
Aft Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46024668&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX367209(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aft Pharmaceuticals Ltd filed Critical Aft Pharmaceuticals Ltd
Publication of MX367209B publication Critical patent/MX367209B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
MX2015008709A 2010-11-04 2011-10-26 Una composición intravenosa que comprende ibuprofeno y paracetamol en combinación. MX367209B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ58901110 2010-11-04
PCT/NZ2011/000226 WO2012060719A1 (en) 2010-11-04 2011-10-26 A combination composition

Publications (1)

Publication Number Publication Date
MX367209B true MX367209B (es) 2019-07-22

Family

ID=46024668

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015008709A MX367209B (es) 2010-11-04 2011-10-26 Una composición intravenosa que comprende ibuprofeno y paracetamol en combinación.
MX2013005113A MX2013005113A (es) 2010-11-04 2011-10-26 Una composicion combinada.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2013005113A MX2013005113A (es) 2010-11-04 2011-10-26 Una composicion combinada.

Country Status (28)

Country Link
US (6) US20130225685A1 (enExample)
EP (1) EP2635269B1 (enExample)
JP (2) JP2013541583A (enExample)
KR (1) KR101900520B1 (enExample)
CN (2) CN103298464A (enExample)
AU (1) AU2011324137B2 (enExample)
BR (1) BR112013010829B8 (enExample)
CA (1) CA2814057C (enExample)
CL (1) CL2013001250A1 (enExample)
CO (1) CO6771406A2 (enExample)
CY (1) CY1123398T1 (enExample)
DK (1) DK2635269T3 (enExample)
ES (1) ES2742373T3 (enExample)
HR (1) HRP20191489T1 (enExample)
HU (1) HUE045442T2 (enExample)
LT (1) LT2635269T (enExample)
MX (2) MX367209B (enExample)
MY (1) MY160572A (enExample)
NZ (1) NZ609727A (enExample)
PH (2) PH12013500689A1 (enExample)
PL (1) PL2635269T3 (enExample)
PT (1) PT2635269T (enExample)
RS (1) RS59258B1 (enExample)
RU (2) RU2707089C2 (enExample)
SG (1) SG189319A1 (enExample)
SI (1) SI2635269T1 (enExample)
SM (1) SMT201900481T1 (enExample)
WO (1) WO2012060719A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130225685A1 (en) 2010-11-04 2013-08-29 Aft Pharmaceuticals Limited Combination composition
US9072710B2 (en) 2012-03-16 2015-07-07 Cumberland Pharmaceuticals Inc. Injectable ibuprofen formulation
WO2016008546A1 (en) * 2014-07-18 2016-01-21 Everbright Pharmaceuticals S.A.R.L. Aqueous formulation comprising paracetamol and ibuprofen
CA2963916A1 (en) * 2014-10-06 2016-04-14 Cumberland Pharmaceuticals, Inc. Co-administration of intravenous ibuprofen and acetaminophen for treatment of pain
WO2018192664A1 (en) 2017-04-20 2018-10-25 Hyloris Developments Sa METHOD FOR PREPARING A COMPOSITION WITH A LOW DISSOLVED OXYGEN CONTENT, COMPRISING ACETAMINOPHEN, AND OPTIONALLY ONE OR MORE NSAIDs, AND A COMPOSITION OBTAINED THEREOF
AU2018300075B2 (en) * 2017-07-10 2024-02-29 Gel Cap Technologies, LLC Dual release dosage form capsule and methods, devices and systems for making same
US11197830B2 (en) 2019-02-27 2021-12-14 Aft Pharmaceuticals Limited Pharmaceutical composition containing acetaminophen and ibuprofen
US11568752B2 (en) * 2020-01-28 2023-01-31 David Clark Company Incorporated Gateway retrieval alert device for aircraft pushback operations
WO2023281089A2 (en) 2021-07-08 2023-01-12 Krka, D.D., Novo Mesto Pharmaceutical composition comprising naproxen and paracetamol
GR1010809B (el) * 2023-09-13 2024-10-25 Ιουλια Τσετη Υδατικο διαλυμα ιβουπροφαινης παρακεταμολης για χρηση σε ενδοφλεβια χορηγηση
AU2024281739A1 (en) 2023-06-02 2025-11-27 Ioulia Tseti Pharmaceutical composition comprising ibuprofen
GR1010769B (el) * 2023-07-27 2024-09-18 Ιουλια Κλεωνος Τσετη Υδατικο διαλυμα ιβουπροφαινης για χρηση σε ενδοφλεβια χορηγηση

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997020551A1 (en) * 1995-12-05 1997-06-12 Adcock Ingram Limited Pharmaceutical composition comprising a skeletal muscle relaxant, a non-steroidal antiinflammatory agent and an analgesic
DE60114249T2 (de) * 2001-11-02 2006-05-18 Cumberland Pharmaceuticals Inc., Nashville Pharmazeutische zusammensetzung mit 2-(4-isobutylphenyl) propionsäure
JP2006514982A (ja) * 2003-03-21 2006-05-18 マクニール−ピーピーシー・インコーポレイテッド 非ステロイド抗炎症薬投薬計画
US20080275125A1 (en) * 2004-07-07 2008-11-06 Aft Pharmaceuticals Limited Combination Composition
KR20060072839A (ko) * 2004-12-23 2006-06-28 김경태 아세트아미노펜과 이부프로펜을 이용하여 통증조절과 해열작용을 하는 주사제
US7934627B2 (en) * 2005-10-13 2011-05-03 Alcoa Inc. Apparatus and method for high pressure extrusion with molten aluminum
KR20090094076A (ko) * 2006-10-20 2009-09-03 맥네일-피피씨, 인코포레이티드 아세트아미노펜/이부프로펜 병용물
WO2008079818A2 (en) * 2006-12-21 2008-07-03 Soluprin Pharmaceuticals, Inc. Intravenous administration of water soluble analgesic formulations
US20090264530A1 (en) * 2008-04-16 2009-10-22 Nickell Robert P Combined nsaid and acetaminophen formulation and method
AU2009304002B9 (en) * 2008-10-14 2014-06-26 Aft Pharmaceuticals Limited A medicinal product and treatment
JP2012523377A (ja) * 2009-03-12 2012-10-04 カンバーランド ファーマスーティカルズ インコーポレイテッド 静脈内イブプロフェンの投与
MY164112A (en) * 2010-07-07 2017-11-30 Aft Pharmaceuticals Ltd A combination composition comprising ibuprofen and paracetamol
US20130225685A1 (en) 2010-11-04 2013-08-29 Aft Pharmaceuticals Limited Combination composition
CA2963916A1 (en) * 2014-10-06 2016-04-14 Cumberland Pharmaceuticals, Inc. Co-administration of intravenous ibuprofen and acetaminophen for treatment of pain

Also Published As

Publication number Publication date
US20130225685A1 (en) 2013-08-29
CN107519159A (zh) 2017-12-29
BR112013010829B1 (pt) 2021-12-21
JP6353577B2 (ja) 2018-07-04
SG189319A1 (en) 2013-05-31
US20230000805A1 (en) 2023-01-05
KR101900520B1 (ko) 2018-09-19
HUE045442T2 (hu) 2019-12-30
US20240207210A1 (en) 2024-06-27
US20250134839A1 (en) 2025-05-01
SI2635269T1 (sl) 2019-10-30
NZ609727A (en) 2015-07-31
LT2635269T (lt) 2019-09-10
PL2635269T3 (pl) 2019-11-29
AU2011324137B2 (en) 2015-05-07
CN103298464A (zh) 2013-09-11
DK2635269T3 (da) 2019-08-26
RU2013123646A (ru) 2014-12-10
JP2013541583A (ja) 2013-11-14
EP2635269A4 (en) 2014-09-17
US11446266B2 (en) 2022-09-20
EP2635269B1 (en) 2019-05-22
PH12013500689A1 (en) 2013-05-27
US12220392B2 (en) 2025-02-11
AU2011324137A1 (en) 2013-05-02
CO6771406A2 (es) 2013-10-15
ES2742373T3 (es) 2020-02-14
RU2015103107A3 (enExample) 2018-08-20
CA2814057A1 (en) 2012-05-10
CY1123398T1 (el) 2021-10-29
PH12021550804A1 (en) 2022-02-14
CL2013001250A1 (es) 2013-08-30
HRP20191489T1 (hr) 2019-11-15
EP2635269A1 (en) 2013-09-11
RU2015103107A (ru) 2015-06-20
US20160235695A1 (en) 2016-08-18
SMT201900481T1 (it) 2019-11-13
KR20140025314A (ko) 2014-03-04
CA2814057C (en) 2022-02-01
MX2013005113A (es) 2013-06-03
BR112013010829B8 (pt) 2022-01-04
BR112013010829A2 (pt) 2016-08-16
MY160572A (en) 2017-03-15
RS59258B1 (sr) 2019-10-31
US20190029982A1 (en) 2019-01-31
WO2012060719A1 (en) 2012-05-10
JP2017132791A (ja) 2017-08-03
US11896567B2 (en) 2024-02-13
RU2707089C2 (ru) 2019-11-22
PT2635269T (pt) 2019-09-04

Similar Documents

Publication Publication Date Title
MX367209B (es) Una composición intravenosa que comprende ibuprofeno y paracetamol en combinación.
EA201290833A1 (ru) Применение амисульприда в качестве противорвотного средства
CR11724A (es) Agente para tratar enfermedades
CO6311006A2 (es) Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+ efectiva a dosis altas
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
CO6382132A2 (es) Tratamiento de pirfenidona para pacientes con funcion hepatica atipica
AR089509A1 (es) Metodo para tratar la perdida osea alveolar, un implante dental, un anticuerpo antiesclerostina, un gel o matriz que comprende dicho anticuerpo y uso
CO2019000938A2 (es) Moduladores nmda espiro-lactam y métodos de uso de los mismos
UY31205A1 (es) Composiciones de tabletas de desintegracion oral de lamotrigina
MX2015009772A (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
MX2009011444A (es) Titulacion del tapentadol.
PE20150161A1 (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple
PE20211199A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
CL2012003119A1 (es) Composicion farmaceutica para inyeccion que compende una solucion acuosa de ibuprofeno y trometamol, en que la concentracion de ibuprofeno esta entre 2 y 6 mg/ml, la concentracion de trometamol esta entre 1.8 y 5.8 mg/ml, y el ph esta entre 7,0 y 9,5; y su uso para el tratamiento del dolor, la inflamacion o la fiebre.
ECSP10010567A (es) Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administracion de dronedarona
MY164112A (en) A combination composition comprising ibuprofen and paracetamol
DOP2016000008A (es) Combinación sinergística de paracetamol/celecoxib para el tratamiento de dolor inflamatorio
MX2017013643A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz.
CL2012003065A1 (es) Combinación farmacéutica que comprende ibuprofeno y l-arginina en una proporción en peso de ibuprofeno/l-arginina entre 1.6 y 5.6, con excepción del valor 1.97; composición farmacéutica sólida que contiene a dicha combinación; y su uso en el tratamiento del dolor, inflamación y/o fiebre.
AR061046A1 (es) Mirtazapina para el tratamiento del dolor neuropatico
MX2022012260A (es) Compuestos activos frente a receptores nucleares.
TH152432A (th) องค์ประกอบแบบผสมผสาน
UY32985A (es) Uso de celivarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administracion de celivarona
AR091633A1 (es) Solucion inyectable de acetaminofen para su administracion por via espinal
AR074599A1 (es) Combinacion antitumoral que asocia ave8062 y docetaxel